Baker Botts Reps Depomed In $1B J&J Unit Drug Rights Deal
Baker Botts LLP-guided Depomed Inc. said Thursday it will pay Belgian drugmaker Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, $1.05 billion to acquire the U.S. rights to its Nucynta...To view the full article, register now.
Already a subscriber? Click here to view full article